Clinical-stage CDMO providing early-stage formulation, device and analytical development plus GMP aseptic and terminal‑sterilized clinical-batch fill/finish for injectable containers (vials, syringes). Proprietary controlled‑release platform enables ready‑to‑use controlled‑release and ultra‑high‑concentration injectables for small molecules to biologics (peptides, proteins, fusion proteins, toxins, mAbs) across endocrine, oncology, infectious, dermatological and ocular programs from preclinical to clinical stages.